Month: March 2017

Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women

CRANBURY, N.J., March 20, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial …

Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women Read More »

Palatin Technologies To Present At The 29th Annual ROTH Conference

Mar 09, 2017, 15:00 ET CRANBURY, N.J., March 9, 2017 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that it will be presenting at the 29th Annual ROTH Conference on Tuesday, March 14, 2017, at 11:00 a.m. Pacific Time.  The conference will be held at The Ritz Carlton Laguna Niguel in Dana Point, CA. …

Palatin Technologies To Present At The 29th Annual ROTH Conference Read More »

Scroll to Top